ATAI Life Sciences

Yahoo Finance • 18 days ago

AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances

AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances Proactive uses images sourced from Shutterstock AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is preparing to launch its pivotal Phase 3 program for its lead treat... Full story

Yahoo Finance • last month

Jefferies analyst says Trump's executive order on psychedelics is an 'official stamp of validation' for investors

Psychedelic drugmakers just got a jolt that Wall Street couldn't ignore. After President Donald Trump signed an executive order (1) aimed at fast-tracking research and access to psychedelic therapies as a form of mental-health treatment, i... Full story

Yahoo Finance • last month

AtaiBeckley's EMP-01 Shows Large And Consistent Improvements In Social Anxiety Disorder

(RTTNews) - AtaiBeckley Inc. (ATAI) announced additional Phase 2a results for EMP-01, its oral R-MDMA candidate, showing clinically meaningful and consistent improvements in adults with social anxiety disorder (SAD). The findings were pres... Full story

Yahoo Finance • last month

What’s Guggenheim Updates View on AtaiBeckley Inc (ATAI)?

AtaiBeckley Inc (NASDAQ:ATAI) is among the must-buy penny stocks to invest in now. The stock has gained more than 180% over the past 12 months. On April 17, Guggenheim lifted its price target on AtaiBeckley Inc (NASDAQ:ATAI) to $16 from $1... Full story

Yahoo Finance • last month

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE - a 38% and 32% reduction,... Full story

Yahoo Finance • last month

Stocks making the biggest moves midday: Stanley Black & Decker, American Airlines, Dow, Marvell Technology & more

Check out the companies making the biggest moves in midday trading: Stanley Black & Decker — The power toolmaker jumped more than 4% after it said recent changes to Section 232 tariffs aren't supposed to have a material impact on its full-... Full story

Yahoo Finance • last month

Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar

Over the weekend, President Donald Trump fast-tracked the approval process for psychedelic treatments for mental illnesses. Trump signed an order that directs the Food and Drug Administration (FDA) to ease restrictions on and speed up rev... Full story

Yahoo Finance • last month

Marvell–Google AI talks, Trump EO boosts psychedelic stocks

Yahoo Finance's Julie Hyman and Brooke DiPalma takes a closer look at some of Monday morning's trending tickers and stories. Marvell (MRVL) stock is surging on reports that the company is in talks with Google (GOOG, GOOGL) to develop arti... Full story

Yahoo Finance • last month

Trump issues executive order on psychedelic drugs

[President Trump Signs Executive Order At The White House] Tasos Katopodis/Getty Images News President Donald Trump on Saturday signed an executive order to expedite access to research and treatments ​based on psychedelic drugs, a move th... Full story

Yahoo Finance • last month

Trump Trade: President to sign order on psychedelic used for PTSD

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly. Claim 30% Off TipRanks Unlock hed... Full story

Yahoo Finance • 2 months ago

AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts

AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts Proactive uses images sourced from Shutterstock Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating an... Full story

Yahoo Finance • 2 months ago

AtaiBeckley added to major US indices, increasing reach among passive investors

AtaiBeckley added to major US indices, increasing reach among passive investors Proactive uses images sourced from Shutterstock AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that it has been added to a series of major US equity benc... Full story

Yahoo Finance • 2 months ago

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenie... Full story

Yahoo Finance • 3 months ago

AtaiBeckley Advances BPL-003 Into Phase 3 For Treatment-Resistant Depression

(RTTNews) - AtaiBeckley Inc. (ATAI) is moving forward with its pivotal Phase 3 program for BPL-003, a nasal spray therapy designed for patients with treatment-resistant depression (TRD). The company confirmed the program is on track to beg... Full story

Yahoo Finance • 3 months ago

AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best new penny stocks to buy. On March 6, AtaiBeckley reported full-year 2025 earnings, which were highlighted by the pivotal execution phase following the strategic combination of Atai Life Sci... Full story

Yahoo Finance • 3 months ago

AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg

[The arrow hit the highlighted yellow target.] Andrii Yalanskyi AtaiBeckley (ATAI [https://seekingalpha.com/symbol/ATAI]) is in talks with advisors to explore strategic options for BPL-003, its lead psychedelic drug candidate, seeking at... Full story

Yahoo Finance • 3 months ago

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track for VLS-01 Phase 2 Elumina trial t... Full story

Yahoo Finance • 3 months ago

AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best low cost stocks to buy under $5. On March 3, AtaiBeckley announced a successful End-of-Phase 2 meeting with the FDA regarding BPL-003, a proprietary intranasal formulation of mebufotenin be... Full story

Yahoo Finance • 3 months ago

AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study

AtaiBeckley Inc (NASDAQ:ATAI) is among the 13 best NASDAQ penny stocks to buy according to analysts. On February 26, AtaiBeckley Inc (NASDAQ:ATAI) reported topline results from a Phase 2a trial of its drug candidate EMP-01 (oral R-MDMA), w... Full story

Yahoo Finance • 3 months ago

AtaiBeckley names Michael Faerm as finance chief

AtaiBeckley names Michael Faerm as finance chief Proactive uses images sourced from Shutterstock AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as... Full story